Measurement of von Willebrand factor cleaving protease (ADAMST-13): Results of an international collaborative study involving 11 method testing the same set of coded plasmas

A. Tripodi, V. Chantarangkul, M. Böhm, U. Budde, J. F. Dong, K. D. Friedman, M. Galbusera, J. P. Girma, J. Moake, M. E. Rick, J. D. Studt, P. L. Turecek, P. M. Mannucci

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: ADAMTS-13 is a von Willebrand factor (VFW)-cleaving protease. Its congenital or acquired deficiency is associated with thrombotic thrombocytopenic purpura (TTP) and more rarely with the hemolytic uremic syndrome. We report on a survey evaluating 11 methods for ADAMTS-13 measurement performed in different labs. Design: Two plasmas, one normal and one from a patient with familial TTP, were mixed at the co-ordinating center to prepare 6 plasmas with 0%, 10%, 20%, 40%, 80% and 100% ADAMTS-13 levels. Each plasma was aliquoted and assembled into sets of 60 (coded from 1 to 60), each containing 10 copies of the original 6 plasmas. Plasmas were frozen and shipped in dry ice to 10 labs with a common frozen reference plasma. Laboratories were asked to measure ADAMTS-13 with their methods. Results were sent to the coordinating center for statistical analysis. Results: Of the 10 methods performed under static conditions 9 were quantitative and one was semiquantitative. One method performed under flow conditions evaluated the extent of cleavage of endothelial cell-derived ultralarge VWF string-like structures and expressed results as deficient, normal, or borderline. Linearity (expected-vs-observed levels), assessed as the squared correlation coefficient, ranged from 0.98 to 0.39. Reproducibility, expressed as the coefficient of variation for repeated measurements, ranged from <10% to 83%. The majority of methods were able to discriminate between different ADAMTS-13 levels. The majority were able to detect the plasma with 0% level and some of them to discriminate between 0% and 10%. Overall the best performance was observed for three methods measuring cleaved VWF by ristocetin cofactor, collagen binding, and immunoblotting of degraded multimers of VWF substrate, respectively. The poor interlaboratory agreement of results was hardly affected by the use of the common standard. The method performed under flow conditions identified the plasmas with 0%, 10%, 20% and 40% activity as deficient in 7, 5, 1 and 3 of the 10 replicate measurements. The plasmas with 80% and 100% were identified as normal in all of the 10 replicate measurements. Conclusions: The survey shows varied performance, but supports an optimistic view about the reliability of current methods for ADAMTS-13.

Original languageEnglish
Pages (from-to)1601-1609
Number of pages9
JournalJournal of Thrombosis and Haemostasis
Volume2
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Thrombotic Thrombocytopenic Purpura
Dry Ice
ADAMTS13 Protein
Hemolytic-Uremic Syndrome
von Willebrand Factor
Immunoblotting
Collagen
Endothelial Cells
Surveys and Questionnaires

Keywords

  • ADAMST-13
  • Hemolytic uremic syndrome
  • Thrombotic microangipathy
  • Thrombotic thrombocytopenic purpura (TTP)
  • von Willebrand factor
  • von Willebrand factor cleaving protease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Measurement of von Willebrand factor cleaving protease (ADAMST-13) : Results of an international collaborative study involving 11 method testing the same set of coded plasmas. / Tripodi, A.; Chantarangkul, V.; Böhm, M.; Budde, U.; Dong, J. F.; Friedman, K. D.; Galbusera, M.; Girma, J. P.; Moake, J.; Rick, M. E.; Studt, J. D.; Turecek, P. L.; Mannucci, P. M.

In: Journal of Thrombosis and Haemostasis, Vol. 2, No. 9, 09.2004, p. 1601-1609.

Research output: Contribution to journalArticle

Tripodi, A. ; Chantarangkul, V. ; Böhm, M. ; Budde, U. ; Dong, J. F. ; Friedman, K. D. ; Galbusera, M. ; Girma, J. P. ; Moake, J. ; Rick, M. E. ; Studt, J. D. ; Turecek, P. L. ; Mannucci, P. M. / Measurement of von Willebrand factor cleaving protease (ADAMST-13) : Results of an international collaborative study involving 11 method testing the same set of coded plasmas. In: Journal of Thrombosis and Haemostasis. 2004 ; Vol. 2, No. 9. pp. 1601-1609.
@article{b593717bced240cb8af66d3b65a20431,
title = "Measurement of von Willebrand factor cleaving protease (ADAMST-13): Results of an international collaborative study involving 11 method testing the same set of coded plasmas",
abstract = "Background: ADAMTS-13 is a von Willebrand factor (VFW)-cleaving protease. Its congenital or acquired deficiency is associated with thrombotic thrombocytopenic purpura (TTP) and more rarely with the hemolytic uremic syndrome. We report on a survey evaluating 11 methods for ADAMTS-13 measurement performed in different labs. Design: Two plasmas, one normal and one from a patient with familial TTP, were mixed at the co-ordinating center to prepare 6 plasmas with 0{\%}, 10{\%}, 20{\%}, 40{\%}, 80{\%} and 100{\%} ADAMTS-13 levels. Each plasma was aliquoted and assembled into sets of 60 (coded from 1 to 60), each containing 10 copies of the original 6 plasmas. Plasmas were frozen and shipped in dry ice to 10 labs with a common frozen reference plasma. Laboratories were asked to measure ADAMTS-13 with their methods. Results were sent to the coordinating center for statistical analysis. Results: Of the 10 methods performed under static conditions 9 were quantitative and one was semiquantitative. One method performed under flow conditions evaluated the extent of cleavage of endothelial cell-derived ultralarge VWF string-like structures and expressed results as deficient, normal, or borderline. Linearity (expected-vs-observed levels), assessed as the squared correlation coefficient, ranged from 0.98 to 0.39. Reproducibility, expressed as the coefficient of variation for repeated measurements, ranged from <10{\%} to 83{\%}. The majority of methods were able to discriminate between different ADAMTS-13 levels. The majority were able to detect the plasma with 0{\%} level and some of them to discriminate between 0{\%} and 10{\%}. Overall the best performance was observed for three methods measuring cleaved VWF by ristocetin cofactor, collagen binding, and immunoblotting of degraded multimers of VWF substrate, respectively. The poor interlaboratory agreement of results was hardly affected by the use of the common standard. The method performed under flow conditions identified the plasmas with 0{\%}, 10{\%}, 20{\%} and 40{\%} activity as deficient in 7, 5, 1 and 3 of the 10 replicate measurements. The plasmas with 80{\%} and 100{\%} were identified as normal in all of the 10 replicate measurements. Conclusions: The survey shows varied performance, but supports an optimistic view about the reliability of current methods for ADAMTS-13.",
keywords = "ADAMST-13, Hemolytic uremic syndrome, Thrombotic microangipathy, Thrombotic thrombocytopenic purpura (TTP), von Willebrand factor, von Willebrand factor cleaving protease",
author = "A. Tripodi and V. Chantarangkul and M. B{\"o}hm and U. Budde and Dong, {J. F.} and Friedman, {K. D.} and M. Galbusera and Girma, {J. P.} and J. Moake and Rick, {M. E.} and Studt, {J. D.} and Turecek, {P. L.} and Mannucci, {P. M.}",
year = "2004",
month = "9",
doi = "10.1111/j.1538-7836.2004.00879.x",
language = "English",
volume = "2",
pages = "1601--1609",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Measurement of von Willebrand factor cleaving protease (ADAMST-13)

T2 - Results of an international collaborative study involving 11 method testing the same set of coded plasmas

AU - Tripodi, A.

AU - Chantarangkul, V.

AU - Böhm, M.

AU - Budde, U.

AU - Dong, J. F.

AU - Friedman, K. D.

AU - Galbusera, M.

AU - Girma, J. P.

AU - Moake, J.

AU - Rick, M. E.

AU - Studt, J. D.

AU - Turecek, P. L.

AU - Mannucci, P. M.

PY - 2004/9

Y1 - 2004/9

N2 - Background: ADAMTS-13 is a von Willebrand factor (VFW)-cleaving protease. Its congenital or acquired deficiency is associated with thrombotic thrombocytopenic purpura (TTP) and more rarely with the hemolytic uremic syndrome. We report on a survey evaluating 11 methods for ADAMTS-13 measurement performed in different labs. Design: Two plasmas, one normal and one from a patient with familial TTP, were mixed at the co-ordinating center to prepare 6 plasmas with 0%, 10%, 20%, 40%, 80% and 100% ADAMTS-13 levels. Each plasma was aliquoted and assembled into sets of 60 (coded from 1 to 60), each containing 10 copies of the original 6 plasmas. Plasmas were frozen and shipped in dry ice to 10 labs with a common frozen reference plasma. Laboratories were asked to measure ADAMTS-13 with their methods. Results were sent to the coordinating center for statistical analysis. Results: Of the 10 methods performed under static conditions 9 were quantitative and one was semiquantitative. One method performed under flow conditions evaluated the extent of cleavage of endothelial cell-derived ultralarge VWF string-like structures and expressed results as deficient, normal, or borderline. Linearity (expected-vs-observed levels), assessed as the squared correlation coefficient, ranged from 0.98 to 0.39. Reproducibility, expressed as the coefficient of variation for repeated measurements, ranged from <10% to 83%. The majority of methods were able to discriminate between different ADAMTS-13 levels. The majority were able to detect the plasma with 0% level and some of them to discriminate between 0% and 10%. Overall the best performance was observed for three methods measuring cleaved VWF by ristocetin cofactor, collagen binding, and immunoblotting of degraded multimers of VWF substrate, respectively. The poor interlaboratory agreement of results was hardly affected by the use of the common standard. The method performed under flow conditions identified the plasmas with 0%, 10%, 20% and 40% activity as deficient in 7, 5, 1 and 3 of the 10 replicate measurements. The plasmas with 80% and 100% were identified as normal in all of the 10 replicate measurements. Conclusions: The survey shows varied performance, but supports an optimistic view about the reliability of current methods for ADAMTS-13.

AB - Background: ADAMTS-13 is a von Willebrand factor (VFW)-cleaving protease. Its congenital or acquired deficiency is associated with thrombotic thrombocytopenic purpura (TTP) and more rarely with the hemolytic uremic syndrome. We report on a survey evaluating 11 methods for ADAMTS-13 measurement performed in different labs. Design: Two plasmas, one normal and one from a patient with familial TTP, were mixed at the co-ordinating center to prepare 6 plasmas with 0%, 10%, 20%, 40%, 80% and 100% ADAMTS-13 levels. Each plasma was aliquoted and assembled into sets of 60 (coded from 1 to 60), each containing 10 copies of the original 6 plasmas. Plasmas were frozen and shipped in dry ice to 10 labs with a common frozen reference plasma. Laboratories were asked to measure ADAMTS-13 with their methods. Results were sent to the coordinating center for statistical analysis. Results: Of the 10 methods performed under static conditions 9 were quantitative and one was semiquantitative. One method performed under flow conditions evaluated the extent of cleavage of endothelial cell-derived ultralarge VWF string-like structures and expressed results as deficient, normal, or borderline. Linearity (expected-vs-observed levels), assessed as the squared correlation coefficient, ranged from 0.98 to 0.39. Reproducibility, expressed as the coefficient of variation for repeated measurements, ranged from <10% to 83%. The majority of methods were able to discriminate between different ADAMTS-13 levels. The majority were able to detect the plasma with 0% level and some of them to discriminate between 0% and 10%. Overall the best performance was observed for three methods measuring cleaved VWF by ristocetin cofactor, collagen binding, and immunoblotting of degraded multimers of VWF substrate, respectively. The poor interlaboratory agreement of results was hardly affected by the use of the common standard. The method performed under flow conditions identified the plasmas with 0%, 10%, 20% and 40% activity as deficient in 7, 5, 1 and 3 of the 10 replicate measurements. The plasmas with 80% and 100% were identified as normal in all of the 10 replicate measurements. Conclusions: The survey shows varied performance, but supports an optimistic view about the reliability of current methods for ADAMTS-13.

KW - ADAMST-13

KW - Hemolytic uremic syndrome

KW - Thrombotic microangipathy

KW - Thrombotic thrombocytopenic purpura (TTP)

KW - von Willebrand factor

KW - von Willebrand factor cleaving protease

UR - http://www.scopus.com/inward/record.url?scp=19944431129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944431129&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2004.00879.x

DO - 10.1111/j.1538-7836.2004.00879.x

M3 - Article

C2 - 15333037

AN - SCOPUS:19944431129

VL - 2

SP - 1601

EP - 1609

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 9

ER -